IntegraGen

IntegraGen

Evry, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $48.4M

Overview

IntegraGen is a France-based provider of genomic services and diagnostic solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company serves academic researchers, clinical and translational research organizations, and biopharma/CROs with a focus on oncology and constitutional genetics. Its business model combines fee-for-service genomics with the distribution of CE-IVD certified software like VarSome Clinical for variant interpretation, positioning it at the intersection of research services and clinical diagnostics.

OncologyGenetic Diseases

Technology Platform

Next-generation sequencing (NGS) services combined with proprietary and partnered bioinformatics software for variant interpretation, including the CE-IVD certified VarSome Clinical platform for constitutional genetics and proprietary tools like MERCURY for tumor analysis and GeCo for advanced bioinformatics.

Funding History

3
Total raised:$48.4M
IPO$25.4M
Series B$15M
Series A$8M

Opportunities

The growing clinical adoption of NGS for personalized medicine and the high unmet need in oncology for sensitive Minimal Residual Disease (MRD) monitoring present significant expansion opportunities.
Distributing certified software like VarSome Clinical allows IntegraGen to capture value in the rapidly growing market for clinical genetic interpretation and reporting.

Risk Factors

The company faces intense competition in both the genomics services and clinical diagnostics markets, requiring continuous innovation.
Regulatory hurdles for new diagnostic tests, particularly in different international markets, could delay commercialization and increase costs.

Competitive Landscape

IntegraGen competes with large, global genomics service providers (e.g., Eurofins, Novogene) and specialized bioinformatics software companies. In the MRD space, it faces competition from established diagnostic companies and startups developing liquid biopsy assays. Its partnership-based distribution model for VarSome Clinical positions it against other clinical variant interpretation platforms like Fabric Genomics, Sophia Genetics, and Qiagen Clinical Insight.